KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short term Debt (2016 - 2025)

Pacira BioSciences has reported Short term Debt over the past 14 years, most recently at $202.4 million for Q2 2025.

  • For Q2 2025, Short term Debt changed N/A year-over-year to $202.4 million; the TTM value through Jun 2025 reached $202.4 million, changed N/A, while the annual FY2024 figure was $201.8 million, 2235.1% up from the prior year.
  • Short term Debt for Q2 2025 was $202.4 million at Pacira BioSciences, roughly flat from $202.1 million in the prior quarter.
  • Over five years, Short term Debt peaked at $350.5 million in Q4 2021 and troughed at $8.6 million in Q4 2023.
  • A 5-year average of $117.3 million and a median of $151.6 million in 2021 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: crashed 90.4% in 2022 and later soared 2238.69% in 2025.
  • Year by year, Short term Debt stood at $350.5 million in 2021, then crashed by 90.4% to $33.6 million in 2022, then tumbled by 74.32% to $8.6 million in 2023, then surged by 2235.1% to $201.8 million in 2024, then rose by 0.31% to $202.4 million in 2025.
  • Business Quant data shows Short term Debt for PCRX at $202.4 million in Q2 2025, $202.1 million in Q1 2025, and $201.8 million in Q4 2024.